The effect of glucagon-like peptide 1 receptor agonists on patients with joint infections was a popular topic at the American ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...

Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Medtronic plc , a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evoluttm ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...

Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide ...

Study underscores the direct vascular effects of this class of drugs, researchers say AURORA, CO / ACCESS Newswire / March 29, 2025 / A novel study of a semaglutide, a glucagon-like peptide-1 (GLP-1) ...